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Background: Depressive/anxiety disorders are the most common types of mental illnesses in the world. The
present study was the first to explore the association between plasma microRNAs (miRNAs) and depression/anxiety
in primary care patients.
Results: In total, 169 patients (aged 20–64 years) from 16 primary health centers were enrolled in the present
study. The healthy controls were consisted of 52 individuals. We first performed miRNA screening of plasma
samples from 11 patients using a Serum/Plasma Focus microRNA Panel comprising 179 miRNA primer sets. Six
miRNAs were differentially expressed and were then validated by quantitative real-time (qRT)-PCR in the entire study
cohort. The mean plasma miR-144-5p level in the depression/anxiety patients increased significantly compared to
baseline (p < 0.0001) after the 8-week follow-up. No significant associations were found between the differentially
expressed miRNAs and a change in the Montgomery-Åsberg Depression Rating Scale (MADRS-S) score after the
follow-up. In linear regression analysis, the plasma miR-144-5p expression level was inversely related to the
depression score (MADRS-S) (β = −0.02, p < 0.01), after adjustment for sex and age, at baseline. In addition, plasma
miR-144-5p levels at baseline in the depression/anxiety patients were significantly lower compared with the healthy
controls (p < 0.001).
Conclusions: Our findings show that plasma miR-144-5p levels are associated with depressive symptoms. Although
confirmatory analyses are required, plasma miRNA-144-5p is a potential peripheral biomarker for pathologic
processes related to depression.
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Depression and anxiety are common mental disorders.
The World Health Organization (WHO) has predicted
that depression will become the second leading contribu-
tor to disease burden by the year 2020 [1]. In different
European studies, approximately 15 to 32 % of patients
who visited primary health care centers showed symptoms
of depression, anxiety, and stress-related disorders [2–5].
These in primary health care common psychiatric dis-
orders are associated with poor quality of life and reduced
life expectancy, placing a large economic burden on
society. Several studies have explored the underlying* Correspondence: xiao.wang@med.lu.se
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Current evidence suggests that the onset and progression
of depression appear to be influenced by multiple factors,
including neurotransmitter systems [9, 10], stress [7, 11],
and genetic susceptibility [7, 12]. However, the molecu-
lar pathophysiology underlying depression and anxiety
is still not fully understood. In recent years, the
emergence of small noncoding RNAs as regulators of
gene expression have gained much attention in various
disease pathophysiologies. MicroRNAs are some of the
most studied and well characterized among small non-
coding RNAs. [13–17].
MicroRNAs (miRNAs) are a class of small (21-23-
nucleotide), noncoding, single-stranded RNAs that
inhibit gene expression by promoting messenger-RNA
(mRNA) degradation or inhibiting translation [18].
They influence a variety of physiological cell processes
during development and tissue homeostasis byicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Characteristics of the patients in the whole cohort
Variable The whole cohort (n = 169)
Baseline MADRS-S 20 (11)
Median score (IQR)
Follow-up MADRS-S 11 (10)
Median score (IQR)
Baseline HADS-D 8 (5)
Median score (IQR)
Follow-up HADS-D 4 (4)
Median score (IQR)
Baseline HADS-A 12 (5.7)
Median score (IQR)
Follow-up HADS-A 7 (4)
Median score (IQR)
Baseline PHQ-9 12 (9)
Median score (IQR)
Follow-up PHQ-9 6 (6)
Median score (IQR)








IQR interquartile range, SD standard deviation
a16 patients had missing data for antidepressants, and 24 had missing data
for tranquilizers
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genes [19]. MicroRNAs are highly expressed in neu-
rons, where they regulate processes of brain develop-
ment, including neurogenesis, neuronal proliferation,
metabolism, and apoptosis [20]. Aberrant expression or
dysregulation of miRNA processing has been linked to
many neurological and psychiatric diseases. Studies in
postmortem brains from patients with Alzheimer’s
disease, schizophrenia, bipolar disorder, and major
depressive disorders showed alterations in several
miRNAs [21–24]. Recently, numerous miRNAs have
been detected in several body fluids, including serum,
plasma, and cerebrospinal fluid (CSF) [25]. The profile
of circulating miRNAs changes significantly under
pathological conditions compared to healthy condi-
tions. Circulating miRNAs can be secreted from cells
into the blood in different ways—enclosed in exosomes
or associated with proteins [26–29]. They are resistant
to nuclease digestion, and can be measured repro-
ducibly, which makes them attractive as potential
biomarkers.
Over the past several years, circulating miRNAs, as
potential biomarkers, have been well documented in
many diseases, including cancer, diabetes, and psychi-
atric diseases [13–15, 30–32]. Recently, two studies have
examined circulating miRNA expression in the blood in
patients with major depressive disorder [31, 33] and
found some dysregulated miRNAs. However, these
studies only had small numbers of patients with a focus
on major depressive disorders. A systematic analysis of
plasma miRNAs in depression and anxiety has so far not
been performed.
The present study builds on a previously published ran-
domized controlled trial by our group, where we included
patients with depression/anxiety from 16 primary health
care centers [34] in Sweden in order to compare the ef-
fects of mindfulness treatment with treatment as usual on
depressive/anxiety symptoms. In the present study, we hy-
pothesized that patients with depression/anxiety would
experience a significant change in plasma miRNAs after
an 8-week treatment and that there would be an asso-
ciation between plasma miRNA levels and symptoms of
depression/anxiety at baseline. Using a broad miRNA
screening panel, we identified a group of miRNAs whose
expression differed between baseline and follow-up using
plasma samples from 11 patients who showed a decline
in the Montgomery-Åsberg Depression Rating Scale
(MADRS-S) total score of at least 50 % between base-
line and follow-up. The first aim was to examine whether
the miRNAs that were identified as differentially expressed
after treatment were associated with a response to
treatment. The second aim was to examine the association
between these differentially expressed miRNAs and symp-
toms of depression/anxiety at baseline.Results
Patients’ characteristics
The clinical characteristics of the patients are shown in
Table 1. The mean age in the whole group was 42 years
and more of the participants were women. Most antide-
pressants prescribed at primary health care centers in
Sweden are selective serotonin reuptake inhibitor
(SSRIs) (e.g., citalopram, fluoxetine, and sertraline, data
not shown). The median scores at baseline indicated
mild to moderate symptoms of depression and/or
anxiety. After treatment, the median scores decreased,
indicating none to mild symptoms. A total of 39 % of
the patients had a decrease in MADRS-S score of at
least 50 % after the 8-week treatment compared to base-
line (data not shown in tables).
miRNAs screening data
To increase the chances of identifying miRNAs that are
associated with treatment response, we performed initial
screening of plasma from 11 patients with at least a
Wang et al. Clinical Epigenetics  (2015) 7:69 Page 3 of 850 % decline in MADRS-S total score at follow-up. Six
candidate miRNAs with a >1.5 fold differential expres-
sions between baseline and follow-up were selected
(Additional file 1: Table S1): miR-144-5p, miR-92b-3p,
miR-885-5p, miR-30a-5p, miR-29a-5p, and miR-29b-2-5p.
These six miRNAs were then measured in the entire
cohort. Five of them were detectable in all samples, but
miR-885 was not suitable for further analysis as more than
20 % of patients had Ct values of >35.
Response analysis
The selected five miRNAs were validated in all of the
169 patients at baseline and follow-up. Additional file 2:
Figure S1 shows that after treatment, the mean plasma
miR-144-5p level and miR-30a-5p in the depression/anx-
iety patients increased significantly compared to base-
line, (p < 0.0001 and p = 0.007, respectively). Moreover,
to assess the potential association between candidates’
miRNAs and treatment response, we performed linear
regression analysis between miRNAs changes (ΔΔCt)
and MADRS score change in the patients. However, no
significant associations were found between the changes
of those selected miRNAs and MADRS-S score change
after treatment (Table 2).
Associations of miRNAs with symptoms of depression/
anxiety (cross-sectional study)
Unadjusted linear regression revealed that plasma miR-
144-5p expression level at baseline was inversely related
to MADRS-S score at baseline (β = −0.02, p < 0.01)
(Table 3). Adjustment for sex and age did not affect
these values. The lower the plasma miR-144-5p expres-
sion levels were the higher was the depression score.
Like miR-144-5p, miR-29a-5p showed a significant posi-
tive association with MADRS-S score (β = 0.02,Table 2 Associations between selected miRNAs (ΔΔCt = ΔCtfollow-up-
ΔCtbaseline) and change in MADRS-S for all patients, adjusted
for MADRS-S at baseline, as determined using linear regression
Univariate analysis
β p value 95 % CI
miR-144-5p (n = 160)
MADRS-S −0.004 0.68 −0.02; 0.01
miR-29a-5p (n = 153)a
MADRS-S −0.005 0.65 −0.02; 0.02
miR-29b-2-5p (n = 153)a
MADRS-S −0.002 0.82 −0.02; 0.02
miR-30a-5p (n = 153)a
MADRS-S 0.003 0.72 −0.01; 0.02
miR-92b-3p (n = 160)a
MADRS-S −0.005 0.67 −0.03; 0.02
aInformation (clinical or qRT-PCR) is missing for some patients (Tables 2 and 3)p = 0.04) in the unadjusted regression. After adjustment
for age and sex, the p value (0.06) no longer remained
significant (Table 3). We also corrected for multiple test-
ing according to Bonferroni. We adjusted the individual
p value for each of these five miRNAs and found that
the association between miR-144-5p and the MADRS-S at
baseline was still significant. The relationships between
miR-144-5p and the scores at baseline are also shown for
the other two scales (Additional file 1: Table S2a, b). The
overall pattern for the other two scales was similar to the
results for MADRS-S.
Comparison of miR-144-5p expression in depression/anxiety
patients and healthy controls
Figure 1 shows the relative plasma miR-144-5p expres-
sion levels in the healthy controls and the depression/
anxiety patients before and after the 8-week treatment.
The relative miR-144-5p expression levels at both base-
line and after treatment were significantly lower in the
depression/anxiety patients than in the healthy controls
(p < 0.001). In the depression/anxiety patients, the mean
plasma miR-144-5p level increased significantly after
treatment compared to baseline (p < 0.0001).
Discussion
To our knowledge, this is the first study to investigate
the expression of miRNAs in primary health care
patients with depression/anxiety. Our major findings are
that plasma expression levels of miR-144-5p were in-
versely associated with depression scores at baseline and
that plasma miR-144-5p levels in depressive patients
were significantly lower than in healthy controls. These
findings suggest that miRNA-144-5p may reflect the
pathologic processes of depression. Moreover, we found
that plasma levels of miRNA-144-5p were significantly
higher after treatment compared to baseline levels in de-
pression/anxiety patients. No significant associations
were found between the changes of those differentially
expressed miRNAs and MADRS-S score change after
treatment (response analysis).
The finding of an inverse correlation between plasma
miR-144-5p levels and the MADRS-S at baseline was
also present for the other two depression scores, i.e.,
Hospital Anxiety and Depression Scale (HADS)-D and
PHQ-9; however, the results for HADS-D and PHQ-9
did not reach statistical significance. We applied correc-
tion for multiple testing according to Bonferroni, and
the lack of significance for HADS-D and PHQ-9 may be
due to the sample size in combination with the Bonferroni
correction. An advantage with the MADRS-S is that it is a
commonly used scale for depression [35, 36], which is sen-
sitive to discriminate the severity of depression and it is
therefore preferred in studies where the intention is to
measure core depressive symptoms and states [37].
Table 3 Associations between selected miRNAs (ΔCt at baseline) and MADRS-S for the whole cohort, as determined using linear
regression
Univariate analysis Adjusted analysis
β p value 95 % CI β p value 95 % CI
miR-144-5p (n = 166)
MADRS-S at baseline −0.02 0.009 −0.03; −0.005 −0.02 0.008 −0.03; −0.005
Sex (female vs. male) −0.34 0.03 −0.64; −0.04
Age 0.005 0.28 −0.004; 0.01
miR-29a-5p (n = 159)a
MADRS-S at baseline 0.02 0.04 0.0004; 0.03 0.01 0.06 −0.0005; 0.03
Sex (female vs. male) −0.007 0.97 −0.35; 0.34
Age −0.01 0.04 −0.02; −0.0007
miR-29b-2-5p (n = 159)a
MADRS-S at baseline 0.004 0.62 −0.01; 0.02 0.004 0.61 −0.01; 0.02
Sex (female vs. male) −0.18 0.30 −0.53; 0.16
Age 0.005 0.39 −0.006; 0.01
miR-30a-5p (n = 159)a
MADRS-S at baseline 0.002 0.73 −0.01; 0.02 0.003 0.68 −0.01; 0.02
Sex (female vs. male) 0.24 0.14 −0.07; 0.55
Age 0.0006 0.90 −0.009; 0.01
miR-92b-3p (n = 166)a
MADRS-S at baseline 0.01 0.11 −0.002; 0.02 0.01 0.12 −0.002; 0.02
Sex (female vs. male) 0.04 0.78 −0.23; 0.30
Age −0.003 0.51 −0.01; 0.005
aInformation (clinical or qRT-PCR) is missing for some patients (Tables 2 and 3)
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neous. Thus, identifying patients with depression using
only depression scores or patient self-report may lead to
a delayed or even wrong diagnosis [38, 39]. It is thus ne-
cessary to identify stable biomarkers to help with the
clinical diagnosis of depression and elucidate potential
biological mechanisms. A stable biomarker that is easily
assessed in peripheral blood might be an ideal andFig. 1 Plasma miR-144-5p levels (determined by the 2ΔCt method): data areobjective measure to diagnose or evaluate the stage of de-
pression [40]. Such biomarkers are still lacking. Circulat-
ing miRNAs are stable and easily accessible, which may
enable their application in daily clinical practice. Studies
have reported that circulating miRNAs are released from
specific cells and transferred to recipient cells to exert
their function [41]. Furthermore, aberrant expression of
circulating miRNAs was demonstrated to be related toshown as the mean and 95 % CI. *p: paired t test), #p: linear regression
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based miRNA profiles as fingerprints of diseases. Based on
the evidence described above, the notion of circulating
miRNAs as biomarkers for various diseases has been
expressed.
Strengths of our study are that the present results were
obtained from an randomized controlled trial (RCT) in-
cluding a total of 169 patients, who are representative of
patients in primary health care. Furthermore, this is the
first study to provide evidence that a specific miRNA may
serve as a potential biomarker for the diagnosis of depres-
sion. Presently, the role of circulating miR-144-5p in
depressive disorders remains unclear. However, there are
a few biological mechanisms that can explain our finding.
MiR-144 has broad expression and is enriched in brain,
as well as in normal and malignant hematopoietic cells
and tissues [43]. It is highly conserved and has multiple
predicted targets in both humans and rats [44]. Many
studies have demonstrated that miR-144 is involved in the
response to mood stabilizer treatment [45], stress re-
sponses [46, 47], and aging diseases [48]. Long-term treat-
ment with the mood stabilizers lithium and valproate
significantly up-regulates miR-144 expression in the rat
hippocampus, which is one of the brain regions involved
in mood regulation. Signaling pathways targeted by miR-
144 include the protein kinase C (PKC), Wnt/β-catenin,
and PTEN pathways [45]. Some of them have been shown
to be involved in the development of depression [49, 50].
In addition, miR-144 was reported to be selectively up-
regulated in the aging brain of humans and was suggested
to have neuroprotective functions. miR-144 can inhibit
the expression of ataxin 1 (ATXN1) in human cells, and a
search of the Genetic Association Database shows that
ATXN1 is associated with mental disorders, such as bipo-
lar disorder, schizophrenia, and major depressive disorder
[48]. It is known that stress is an important risk factor for
depression. In one study, circulating miR-144* level chan-
ged with stress associated with the nationally administered
examination for academic promotion in healthy young
adults: miR-144* level was significantly increased after the
examination compared to before the examination [46].
However, there was no correlation between miR-144*
level and anxiety scores [46], which is consistent with
our findings (Additional file 1: Table S2b). We assume
that the increased circulating miR-144 level may reflect
changes in miR-144 expression in the brain, which may
in turn be associated with the progression of depres-
sion. The psychopathological mechanisms of the effect
of miR-144 on depression remain to be elucidated. Our
results, however, is a complement to the recent findings
that decreased levels of miR-144* are associated with
several diseases [51, 52].
Our study is the first RCT to explore the association
of circulating miRNA expression in depression. Despiteour promising results, there are several general limita-
tions to our experimental design that should be consid-
ered when interpreting our results. First, we included
patients with depression as well as anxiety. Overlapping
symptoms could affect our findings. However, overlap-
ping symptoms are relatively common among these con-
ditions and our approach is in line with previous studies.
Second, in the initial screening analysis, we ran one well
instead of duplicates/triplicates for each sample. How-
ever, when we setup technical replicates (duplicates or
triplicates) in our laboratory, the technical variation was
very small. Another limitation is that only six miRNAs
were selected from the initial miRNA screen and
validated in the whole cohort, suggesting that other miR-
NAs that are potentially associated with depression
scores could have been missed in the current study.
However, these selected miRNAs were the only miRNAs
that were differentially expressed. In addition, this is the
first study to examine miRNAs’ potential association
with depression/anxiety, and there is so far no available
standard for selection of candidate miRNAs for screen-
ing. In addition, the correlation between plasma miR-
144-5p expression level and miR-144-5p in the brain is
unknown, as is the source of plasma miR-144-5p.
Conclusions
In summary, our findings show that plasma miR-144-
5p levels are associated with depressive symptoms in a
primary health care setting. In further studies, plasma
miR-144-5p levels need to be measured in patients in
other clinical settings, including major depressive disor-
ders, to examine the validity of our findings. It will also
be of interest to examine whether the expression of
exosomal miR-144-5p is related to depression scores. In
addition, it would be informative to test the predictive
value of miR-144-5p in a larger cohort of patients with
depression.
Methods
Study subjects and sample collection
The study subjects were recruited from 16 primary
health care centers in a RCT of mindfulness group ther-
apy compared to treatment as usual. The RCT included
a group of patients with depression, anxiety or stress,
and adjustment disorder. A detailed description of the
study design is provided in our previous article [34]. The
overall aim of the RCT was to compare the effect of a
structured mindfulness-based group therapy program
with treatment as usual (mostly individual cognitive
behavioral therapy (CBT)) [53]. Briefly, patients were
recruited between 4 Jan 2012 and 22 March 2012 at the
16 primary health centers in urban and rural settings in
Skåne, in the southernmost part of Sweden. The inclu-
sion criteria were as follows: age 20–64 years and a score
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or ≥7 on the HADS or a total score on the MADRS-S of
between 13 and 34 (mild to moderate depression). A
total of 135 patients met the inclusion criteria for
MADRS-S, 118 for HADS-A, 159 for HADS-D, and 111
for PHQ-9. The rationale for using multiple scales to
assess symptoms of depression and anxiety was that dif-
ferent scales are used in clinical practices worldwide
[34]. Eligible patients had a clinical diagnosis of depres-
sion, anxiety or stress, and adjustment disorder, accord-
ing to the International Classification of Diseases (ICD)-
10 criteria. All clinical diagnoses were made by doctors
at the 16 primary health care centers. The exclusion
criteria were as follows: severe personality disorder, risk
of suicide, pregnancy, thyroid disease, current psycho-
therapy of any kind, and participation in any other psy-
chiatric intervention study. The clinical characteristics
and miRNA distributions of the total study population are
presented in Table 1. In total, 169 patients (86 % females,
13 % males, 1 % gender not specified) aged 42 ± 11 years
(mean ± standard deviation) were enrolled in the present
study. All the patients were fluent in Swedish, and 90 %
were born in Sweden and/or had at least a high school
degree (not shown in table). Each patient filled in three
self-rated questionnaires (above mentioned PHQ-9,
HADS-A/HADS-D, and MADRS-S) at baseline and after
8 weeks of follow-up. The patients received antidepres-
sants and tranquilizers if deemed necessary. Blood sam-
ples were collected at the same time as the assessment of
self-rated symptoms before and after treatment. The con-
trol group was consisted of 52 healthy individuals (74 %
females, 26 % males) aged 47 ± 12 years. They were
recruited from all types of personnel groups among the
hospital staff.Plasma collection
For patients, whole blood (6 mL) was collected from
each participant in EDTA tubes. Blood samples were
centrifuged at 2000 g for 10 min at 4 °C, and the plasma
was then aliquoted and stored at −80 °C before further
processing. For healthy controls, whole blood was col-
lected in buffered citrate tubes and centrifuged at 2000 g
for 20 min at room temperature. Blood samples were
processed and plasma frozen within 8 h of collection.Sampling strategy and miRNA analysis
For the miRNA screening, 11 individuals (8 females and 3
males, age 41 ± 9. 2 years) with a minimum reduction in
MADRS-S score of 50 % from the initial evaluation were
selected. We selected those individuals who showed the
largest change in the magnitude of the depressive symp-
toms. We assumed that a linear change in the magnitude
of the depressive symptoms would also be associated withthe magnitude of the depressive/anxiety symptoms at
baseline.
We used MADRS-S score as our selection criteria be-
cause it is a commonly used scale for depression [31, 35,
36, 54]. The individuals in this initial screening analysis
were chosen to resemble the whole group as much as
possible, based on sex and age. Fifty microliter of total
RNA was isolated from 200 μl of plasma using the
Qiagen miRNeasy Mini Kit (Qiagen GmbH, Hilden,
Germany) according to the manufacturer’s protocol,
with minor modifications. miRNAs were reverse tran-
scribed using a Universal cDNA Synthesis kit (Exiqon,
Vedbæk, Denmark). The resulting reverse transcription
reaction product was stored at −20 °C before analysis. A
detailed description of the methodology is provided in a
previous article [30]. miRNA expression was screened
using a Serum/Plasma Focus microRNA PCR Panel (Exi-
qon) comprising 179 LNA™ microRNA primer sets fo-
cusing on serum/plasma-relevant human miRNAs.
Quantitative real-time PCR (qPCR) was conducted using
a CFX384 Real-Time PCR Detection System (Bio-Rad).
Undetectable data were assigned a default threshold
cycle (Ct) value of 36. A mean of 172 miRNAs were
detected in the 11 samples. As there is no current con-
sensus as to an appropriate reference miRNA for the
normalization of plasma miRNAs in qPCR analysis, all
qPCR data were normalized to the Ct average of all
miRNA measurements for each sample [55]. Compari-
son of the 172 miRNAs in the 11 samples revealed six
miRNAs with >1.5 fold differential expression between
baseline and follow-up (Additional file 1: Table S1). We
used a >1.5 fold change between baseline and follow-up
as the cutoff, which is based on several previous profil-
ing studies confirming that a >1.5 fold change in miRNA
expression can have a significant impact on the biology
of the cell [55–57]. These six miRNAs were then
measured in duplicate by qPCR in the whole cohort
(n = 169). miR-451a and miR-23a-3p were used to test
hemolysis in plasma samples [58]. The Ct values were
normalized according to the ΔCt method with the
internal controls miR-425-5p and miR-186-5p. The
normalization stability of those two miRNAs was
confirmed with geNorm software [59]. Ct values were
normalized to miR-425-5p and miR-186-5p using the
following equation: ΔCt = CtmiR-425-5p&miR-186-5p (geo-
metric mean of two miRNAs) − CtmiR of interest. Relative
expression was calculated as 2ΔCt.Ethical considerations
The study was performed according to the principles of
the Declaration of Helsinki. It was reviewed and
approved by the Ethics Committee of Lund University,
prior to its commencement, on 5 October 2011
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was obtained from all participants.Statistical analysis
For the miRNA screening analysis, we tested the difference
between baseline and follow-up using the Wilcoxon
signed-rank test due to the nature of data, repeated mea-
surements and nonnormality (Additional file 1: Table S1).
MADRS-S, HADS-D (depression), HADS-A (anxiety), and
PHQ-9 scores are presented as the median and interquar-
tile range (IQR); age is presented as the mean and standard
deviation (SD); and sex and antidepressant and tranquilizer
use are presented as numbers and percentages (Table 1).
The mean and 95 % confidence interval (CI) at baseline
and follow-up are shown for plasma miR-144-5p levels. A
paired t test was used to test the difference between base-
line and follow-up (Additional file 2: Figure S1). The asso-
ciation between change in miRNA levels and treatment
response was tested using linear regression, adjusted for
MADRS-S at baseline (Table 2). Linear regression was also
used to examine the associations between miRNA levels at
baseline and MADRS-S, HADS-D, HADS-A, and PHQ-9
scores (Table 3 and Additional file 1: Table S2a-S2c). We
considered important potential confounders to be sex, age,
drug treatment (antidepressant and/or tranquilizer), body
mass index (BMI), and smoking. When adjusting the
models for these variables, the beta-coefficients did not
change much (at the most 5 %) and no p values were
significant for drug treatment, BMI, or smoking. Hence,
we kept in the final models only sex and age as adjusting
variables.
Linear regression analyses (adjusted for age and sex)
were used to test the difference of miR-144-5p levels be-
tween healthy controls and patients at baseline and after
treatment (Figure 1). STATA version 12 (StataCorp LP)
was used for all statistical analyses.
Additional files
Additional file 1: Supplementary Tables. Table S1. six candidate
miRNAs with >1.5 fold differential expression between baseline and
follow-up and changes in more than half of the samples (n≥6) were
selected for further validation. Table S2a and Table S2b. The relationships
between miR-144-5p and two depression scores at baseline, HADS-D
(β=-0.02, p=0.02) and PHQ-9 (β=-0.02, p=0.06) were also significant or
borderline significant, whereas the association with HADS-A score
(β=-0.01, p=0.37) was non-significant (Table S2c).
Additional file 2: Figure S1. Supplementary Figure. Plasma 5 miRNAs
levels (determined by the 2ΔCt method)changed after treatment. Data
are shown as the mean and 95 % CI. P calculated with paired t-test
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